- Home
- MOS vs ITCI Comparison
MOS vs ITCI Comparison
Compare MOS & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOS
- ITCI
- Stock Information
- Founded
- MOS 2004
- ITCI 2002
- Country
- MOS United States
- ITCI United States
- Employees
- MOS N/A
- ITCI N/A
- Industry
- MOS Agricultural Chemicals
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- MOS Industrials
- ITCI Health Care
- Exchange
- MOS Nasdaq
- ITCI Nasdaq
- Market Cap
- MOS 8.0B
- ITCI 8.7B
- IPO Year
- MOS 2004
- ITCI N/A
- Fundamental
- Price
- MOS $27.13
- ITCI $126.89
- Analyst Decision
- MOS Buy
- ITCI Buy
- Analyst Count
- MOS 12
- ITCI 13
- Target Price
- MOS $32.20
- ITCI $100.31
- AVG Volume (30 Days)
- MOS 4.4M
- ITCI 2.9M
- Earning Date
- MOS 02-19-2025
- ITCI 02-20-2025
- Dividend Yield
- MOS 3.26%
- ITCI N/A
- EPS Growth
- MOS N/A
- ITCI N/A
- EPS
- MOS 1.15
- ITCI N/A
- Revenue
- MOS $11,456,400,000.00
- ITCI $613,728,000.00
- Revenue This Year
- MOS N/A
- ITCI $48.41
- Revenue Next Year
- MOS $4.09
- ITCI $38.26
- P/E Ratio
- MOS $23.58
- ITCI N/A
- Revenue Growth
- MOS N/A
- ITCI 46.08
- 52 Week Low
- MOS $23.56
- ITCI $62.78
- 52 Week High
- MOS $33.44
- ITCI $128.00
- Technical
- Relative Strength Index (RSI)
- MOS 63.72
- ITCI 87.18
- Support Level
- MOS $24.08
- ITCI $80.83
- Resistance Level
- MOS $26.18
- ITCI $128.00
- Average True Range (ATR)
- MOS 0.72
- ITCI 2.57
- MACD
- MOS 0.32
- ITCI 4.45
- Stochastic Oscillator
- MOS 99.17
- ITCI 97.65
About MOS Mosaic Company (The)
Formed in 2004 by the combination of IMC Global and Cargill's fertilizer business, Mosaic is one of the largest phosphate and potash producers in the world. The company's assets include phosphate rock mines in Florida, Brazil, and Peru and potash mines in Saskatchewan, New Mexico, and Brazil. Mosaic also runs a large fertilizer distribution operation in Brazil through its Mosaic Fertilizantes business, which the company acquired from Vale in 2018.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.